Effects of melatonin on depression and cognition function in hemodialyzed patients, A randomized, double-blind, controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110226005914N3

Enrollment

Registered

2019-02-19

Start date

2018-03-21

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease, Hemodialysis. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group: Patients in the intervention group receive melatonin at a dose of 3 mg per day for two months. Intervention 2: Control group:In the control group, patients are give

Eligibility

Sex/Gender

All

Age

14 Years to 70 Years

Inclusion criteria

Inclusion criteria: They should be hemodialized for at least 3 months and 3 times per week and 4 hours per visit. They should be fluent in Farsi language . They should have visual and auditory health to complete the questionnaire.

Exclusion criteria

Exclusion criteria: Have diabetes type 1 or 2. Have psychotic disease Take antidepressant medicationss. Take anti-anxiety/sedative medications.

Design outcomes

Primary

Measure	Time frame
Depression Score in the Beck Questionnaire.Cognitive impairment Score in the MMSE Questionnaire. Timepoint: Before starting the medication and two months after taking Melatonin tablets. Method of measurement: Beck Depression questionnare and MMSE Cognitive Impairment questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Hatamkhani

Oroumia University of Medical Sciences

hatamkhani@razi.tums.ac.ir+98 44 3223 4897

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026